|
|
Dr. Richardson - Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Resultsof a Phase 1/2 Study.
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors
|
|
|
12.29.07 |
To view the video full screen, click on the small
 button next to the volume control in the
lower right hand corner.
|
 related articles
|
|
back
print